Comparative Pharmacology
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus MONISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISEOFULVIN ULTRAMICROSIZE versus MONISTAT.
GRISEOFULVIN, ULTRAMICROSIZE vs MONISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
Miconazole, the active ingredient in MONISTAT, inhibits fungal CYP51 (lanosterol 14-alpha-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity, leading to cell death.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
Intravaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 2% cream 5 g intravaginally at bedtime for 7 days. Topical: Apply 2% cream twice daily for 2-4 weeks.
None Documented
None Documented
9-24 hours (mean 15 hours); prolonged in liver disease.
Approximately 90-120 minutes; supports twice-daily local dosing.
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Primarily fecal (approximately 90%) as unchanged drug; less than 2% renal elimination.
Category D/X
Category C
Antifungal
Antifungal